Day: November 18, 2020

Syneos Health Announces Upsizing and Pricing of Offering of $600.0 Million of Senior Notes Due 2029

MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the upsizing and pricing of an offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029 (the “Notes”), an upsize of $100.0 million over the amount previously announced. The Notes were priced at par value and will bear an interest rate of 3.625% per annum. The Notes are being offered in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be guaranteed, jointly and severally, on a senior unsecured basis, by certain...

Continue reading

Appulse Corporation: Reporting results for the Nine Months ended September 30, 2020

CALGARY, Alberta, Nov. 18, 2020 (GLOBE NEWSWIRE) — Appulse Corporation (“Appulse”) today reported a net income of $758,000 ($.05 per share) for the nine months ended September 30, 2020 with revenues of $8,006,000, compared to a net income of $363,000 ($.03 per share) and revenues of $7,615,000 for the same nine-month period of the previous year. Operating cash flow (net income adjusted for items not involving cash) for the nine-month period ended September 30, 2020 of $1,168,000 compares to operating cash flow of $953,000 for the same period of 2019. Total shareholder’s equity at September 30, 2020 was $5,154,000 compared to $3,847,000 at September 30, 2019.A 6% reduction in total parts and service sales during the nine-month period was more than offset by a significant increase in machine sale revenues. Management expects 2020 final...

Continue reading

Roman DBDR Tech Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants Commencing November 19, 2020

New York, New York, Nov. 18, 2020 (GLOBE NEWSWIRE) — Roman DBDR Tech Acquisition Corp. (the “Company”) announced today that, commencing November 19, 2020,  holders of the units sold in the Company’s initial public offering may elect to separately trade the shares of Class A common stock and warrants included in the units. Any units not separated will continue to trade on the Nasdaq Stock Market (the “Nasdaq”) under the symbol “DBDRU”, and the shares of Class A common stock and warrants will separately trade on the Nasdaq under the symbols “DBDR” and “DBDRW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, to separate the units into...

Continue reading

Immutep Announces Expansion of TACTI-002 Collaboration Trial

Additional 74 patients with 1st line non-small cell lung cancer (NSCLC) to be enrolled, more than tripling patient numbers in this indicationFollows encouraging interim data from 1st line NSCLC patientsFirst Patient is expected to be enrolled in the expanded trial by the end of 2020Separately, Immutep has initiated planning for a new randomized, controlled Phase II trial in 1st line Head and Neck Squamous Cell Carcinoma (HNSCC) advancing efti into late stage clinical trials in this indicationSYDNEY, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) through the expansion of its ongoing TACTI-002 study and a new Phase II trial.TACTI-002 Expansion with Merck & Co, Inc., Kenilworth,...

Continue reading

Bilibili Inc. Announces Third Quarter 2020 Financial Results

SHANGHAI, China, Nov. 18, 2020 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI), a leading online entertainment platform for young generations in China, today announced its unaudited financial results for the third quarter ended September 30, 2020.Third Quarter 2020 Highlights:Total net revenues reached RMB3,225.7 million (US$475.1 million), a 74% increase from the same period in 2019.Average monthly active users (MAUs) reached 197.2 million, and mobile MAUs reached 183.5 million, representing increases of 54% and 61%, respectively, from the same period in 2019.Average daily active users (DAUs) reached 53.3 million, a 42% increase from the same period in 2019.Average monthly paying users (MPUs1) reached 15.0 million, an 89% increase from the same period in 2019.“We are excited to announce another great...

Continue reading

PyroGenesis Receives Final Approval to Graduate to the Toronto Stock Exchange

MONTREAL, Nov. 18, 2020 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://www.pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to announce that it has received final approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (“TSXV”) and list its common shares (“Common Shares”) on the TSX.The Company’s Common Shares will be listed for trading on the TSX at the opening of markets on Friday, November 20, 2020 under its current trading symbol “PYR”. In connection with the listing of the Common Shares on the TSX, the last day of trading on the TSXV...

Continue reading

Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

Sydney, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is listed on NASDAQ and the Australian Securities Exchange, is pleased to announce that it has today successfully completed a A$29.6 million a private placement of ordinary shares to professional and institutional investors (Placement).Use of FundsThe Company will use the proceeds from the Placement to finance its LAG-3 related clinical programs in immuno-oncology and autoimmune disease. This includes the ongoing clinical development of eftilagimod alpha (“efti” or “IMP321), including the expansion of the Phase II TACTI-002 study through an additional 74 patients with 1st line NSCLC and a new Phase II clinical trial in 1st line HNSCC.  Details of these...

Continue reading

U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept’s U.S. Patent No.10,195,214

MENLO PARK, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a decision upholding the validity of all claims of U.S. Patent No. 10,195,214, “Concomitant Administration of Glucocorticoid Receptor Modulators and CYP3A Inhibitors” (the “‘214 patent”). The ‘214 patent expires in 2037.“We are gratified by the PTAB’s decision,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “The ‘214 patent is directed to an important medical discovery – that, with dose-adjustment as set...

Continue reading

Atlas Technical Consultants, Inc. Announces Completion of Warrant Exchange Offer and Plan to Exchange Remaining Outstanding Warrants

AUSTIN, Texas, Nov. 18, 2020 (GLOBE NEWSWIRE) — Atlas Technical Consultants, Inc. (NASDAQ: ATCX) (“Atlas” or the “Company”), a leading provider of professional testing, inspection, engineering, environmental and consulting services, today announced that, in connection with the completion of its previously announced exchange offer (the “Exchange Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding warrants (the “warrants”) to purchase shares of Class A common stock, par value $0.0001 per share, of the Company (the “common stock”) and the related amendment to the warrant agreement governing the warrants (the “Warrant Amendment”) that was executed on November 17, 2020, the Company plans to exercise its right, in accordance with the terms of the Warrant Amendment, to exchange all remaining untendered...

Continue reading

Fortis Inc. Announces First Quarter Dividends – 2021

ST. JOHN’S, Newfoundland and Labrador, Nov. 18, 2020 (GLOBE NEWSWIRE) — The Board of Directors of Fortis Inc. (“Fortis” or the “Corporation”) (TSX/NYSE: FTS) has declared the following dividends:$0.3063 per share on the First Preference Shares, Series “F” of the Corporation, payable on March 1, 2021 to the Shareholders of Record at the close of business on February 16, 2021; $0.2745625 per share on the First Preference Shares, Series “G” of the Corporation, payable on March 1, 2021 to the Shareholders of Record at the close of business on February 16, 2021; $0.11469 per share on the First Preference Shares, Series “H” of the Corporation, payable on March 1, 2021 to the Shareholders of Record at the close of business on February 16, 2021; $0.094685 per share on the...

Continue reading